Tianjin Chase Sun PharmaceuticalLtd Beheer

Beheer criteriumcontroles 3/4

De CEO Tianjin Chase Sun PharmaceuticalLtd is Dan Zheng, benoemd in Mar2017, heeft een ambtstermijn van 7.67 jaar. bezit rechtstreeks 0.05% van de aandelen van het bedrijf, ter waarde CN¥ 5.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 5.2 jaar.

Belangrijke informatie

Dan Zheng

Algemeen directeur

CN¥2.6m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.7yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	7.7yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

CEO

Dan Zheng (60 yo)

7.7yrs

Tenure

CN¥2,608,700

Compensatie

Ms. Dan Zheng serves as General Manager of Tianjin Chase Sun Pharmaceutical Co.,Ltd since March 24, 2017 and serves as its Vice Chairman since April 24, 2019. She serves as Director of Tianjin Chase Sun Ph...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dan Zheng	GM & Vice Chairman	7.7yrs	CN¥2.61m	0.050% CN¥ 5.9m
Wu Jun Lan	Executive GM	12.9yrs	CN¥1.81m	0.050% CN¥ 5.9m
Wu Sun	Deputy GM	no data	CN¥979.30k	geen gegevens
Chun Xu Li	Deputy GM	no data	CN¥1.11m	0.022% CN¥ 2.7m
Rui Qiang Chen	GM of Human Resource Center & Deputy GM	no data	CN¥1.21m	0.023% CN¥ 2.7m
Kun Zhang	Deputy General Manager	7.7yrs	CN¥1.32m	0.031% CN¥ 3.7m
Xiao Zhong Lu	Deputy General Manager	2.6yrs	CN¥1.76m	geen gegevens

7.7yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300026 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dan Zheng	GM & Vice Chairman	7.6yrs	CN¥2.61m	0.050% CN¥ 5.9m
Wu Jun Lan	Executive GM	5.6yrs	CN¥1.81m	0.050% CN¥ 5.9m
Wu Sun	Deputy GM	5.6yrs	CN¥979.30k	geen gegevens
Chun Xu Li	Deputy GM	less than a year	CN¥1.11m	0.022% CN¥ 2.7m
Xiaoqing Yao	Chairman	24.2yrs	CN¥2.66m	10.24% CN¥ 1.2b
Peng Fei Tu	Independent Director	4.8yrs	CN¥120.00k	geen gegevens
Dan Liang	Employee Representative Member of Supervisory Board & Securities Affairs Representative	11.6yrs	CN¥91.00k	geen gegevens
Shengtian Wang	Independent Director	6.9yrs	CN¥120.00k	geen gegevens
Tao Gong	Independent Director	4.8yrs	CN¥120.00k	geen gegevens
Li Li	Independent Director	4yrs	CN¥120.00k	geen gegevens
Sen Lin	Director	less than a year	geen gegevens	geen gegevens
Juan Chen	Director	1.3yrs	geen gegevens	geen gegevens

5.2yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300026 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Tianjin Chase Sun PharmaceuticalLtd Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 21, 2022

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces the Election of Li Li as an Independent Director

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.051 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 2Q 2023)

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.03 announced

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.06 in 1Q 2023)

New minor risk - Earnings quality

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.21 in FY 2022)

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.21 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.04 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.039 in 2Q 2022)

Tianjin Chase Sun Pharmaceutical Co.,Ltd. Approves Final Cash Dividend for A Shares for the Year 2022, Payable on 12 May 2023

Full year 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.061 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.093 in 2Q 2021)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 19, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.06 in 1Q 2021)

Less than half of directors are independent

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.19 in FY 2020)

Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Cash Dividend for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.061 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.093 (vs CN¥0.067 in 2Q 2020)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.19 (vs CN¥0.14 in FY 2019)

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.07

New 90-day low: CN¥4.26

New 90-day low: CN¥4.52

New 90-day low: CN¥5.01

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces the Election of Li Li as an Independent Director

New 90-day low: CN¥5.27

Third quarter earnings released

New 90-day high - CN¥6.45

Earnings released

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd